Infantile Spasm Treatment Market to Surpass US$ 143.5 Million by 2026

“Infantile Spasm Treatment Market”
Infantile Spasm Treatment Market to Surpass US$ 143.5 Million by 2026. Infantile Spasm Treatment Market is projected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026)

Strong product pipeline and launch of cost-effective generic versions of existing drugs by market players is expected to augment the market growth

Key players in the market are focused on launching cost-effective generic drugs, in order to treat infantile spasm and address the critical unmet needs of patients. For instance, in May 2018, Amneal Pharmaceuticals launched vigabatrin for oral solution USP, which is a generic equivalent for Sabril. This is the second generic vigabatrin product available in the market. Aucta Pharmaceuticals and Upsher-Smith Laboratories, LLC launched vigabatrin for oral solution under the brand name Vigadrone in July 2018, which is another generic version of vigabatrin (Sabril).

As of 2018, there were around 5 novel drug candidates in development. 60% of these drugs are in phase III of development, which are expected to enter the market in the near future, thereby offering effective treatment among the fastest growing markets in the world.

Global Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 111.1 million in 2017 and is projected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Browse 39 Market Data Tables and 29 Figures spread through 150 Pages and in-depth TOC on Infantile Spasm Treatment, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2453

Key players operating in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in April 2014, Mallinckrodt Pharmaceuticals acquired Questcor, a company involved in contract manufacturing services. Questcor has FDA approved H.P. Acthar Gel, an injectable drug for 19 indications such as infantile spasm.

Key Takeaways of the Infantile Spasm Treatment Market:

The global infantile spasm treatment market is expected to exhibit a CAGR of 3.1% over the forecast period, owing to increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases

Among product type, the adrenocorticotropic hormone (ACTH) segment held a dominant position in the infantile spasm treatment market in 2018, owing to low side effects and greater efficacy than other medications

Among route of administration, parenteral segment held dominant position in the infant spasm treatment market in 2018, as the effective drug adrenocorticotropic hormone (ACTH) is available in parenteral form

Key players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Anavex Life Sciences Corp., Catalyst Pharmaceuticals, GW Pharmaceuticals plc, and Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics Inc., Etrophin Inc., and Catalystpharma.

To Get Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2453

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. 

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com/insight/request-customization/2453